Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Malaysia pneumonia treatment drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drugs (Branded, Generics)
5.2.2. By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs, Others)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
5.2.4. By Region (West v/s East)
5.2.5. By Company (2022)
5.3. Market Map
5.3.1. By Drugs
5.3.2. By Drug Class
5.3.3. By Distribution Channel
5.3.4. By Region
6. Malaysia Branded pneumonia treatment drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs, Others)
6.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
7. Malaysia Generics pneumonia treatment drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs, Others)
7.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
8. Market Dynamics
8.1. Drivers
8.2. Challenges
9. Market Trends & Developments
9.1. Recent Development
9.2. Mergers & Acquisitions
9.3. Product Launches
10. Policy & Regulatory Landscape
11. Porter’s Five Forces Analysis
11.1. Competition in the Industry
11.2. Potential of New Entrants
11.3. Power of Suppliers
11.4. Power of Customers
11.5. Threat of Substitute Products
12. Malaysia Economic Profile
13. Competitive Landscape
13.1. Business Overview
13.2. Product Offerings
13.3. Recent Developments
13.4. Financials (As Reported)
13.5. Key Personnel
13.6. SWOT Analysis
13.6.1. GlaxoSmithkline Pharmaceutical Sdn. Bhd.
13.6.2. Pfizer (Malaysia) Sdn Bhd
13.6.3. Sanofi-Aventis (Malaysia) Sdn. Bhd.
13.6.4. Astrazeneca Sdn. Bhd.
13.6.5. Roche (Malaysia) Sdn. Bhd.
13.6.6. Bayer Co. (Malaysia) Sdn Bhd
13.6.7. Cipla Malaysia Sdn Bhd
14. Strategic Recommendations